Table 3.
Starting Dose (J cm−2) |
Further Dosing (J cm−2) |
Frequency | Treatments | MED testing |
Follow- Up (months) |
Patient s |
Side Effects | Recurrence | Complete response |
|
---|---|---|---|---|---|---|---|---|---|---|
Nistico, 2004 [21] |
0.5–1 (Twice MED) |
0.15–0.5/ session |
q 7 to 10 d | 10 | Yes | 12 | 5 | Transient hyperpigmentation, itch |
None | 5 |
Passeron, 2004 [22] |
0.17–0.5 (50mJ below MED) |
0.1/per week | Twice weekly | 21 | Yes | 3 | 5 | Erythema, blistering, | None | 5 |
Mori, 2004 [23] | 0.5–1 (2–3 time MED) |
0.15–0.5/ session |
Weekly | 8 | Yes | 28 | 4 | Erythema, itch | None | 3 of 4 |
Meisenheimer, 2006 [24] |
0.1–0.15 | 0.3/session | Twice weekly | 14 to >38 | Yes | 6 | 2 | Persistent Erythema | 1 of 2 | 1 of 2 |
Kontos, 2006 [25] |
NR | NR | Thrice weekly |
14 to 22 | NR | NR | 2 | Erythema, itch, blisters, eroisions, hyperpigmentation |
1 of 2 | 1 of 2 |
NR- Not Reported